Community Trust & Investment Co. Raises Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Community Trust & Investment Co. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 33.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 68,575 shares of the medical research company’s stock after buying an additional 17,133 shares during the period. IQVIA comprises about 1.3% of Community Trust & Investment Co.’s portfolio, making the stock its 27th biggest position. Community Trust & Investment Co.’s holdings in IQVIA were worth $14,050,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Bishop Rock Capital L.P. raised its position in IQVIA by 14,549.4% in the second quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock worth $18,667,000 after acquiring an additional 4,022,902 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in IQVIA by 1,170.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,364,641 shares of the medical research company’s stock worth $247,191,000 after purchasing an additional 1,257,263 shares in the last quarter. Alliancebernstein L.P. increased its position in IQVIA by 20.1% during the 3rd quarter. Alliancebernstein L.P. now owns 5,157,158 shares of the medical research company’s stock worth $934,167,000 after purchasing an additional 862,222 shares in the last quarter. Marshall Wace LLP boosted its stake in IQVIA by 570.5% in the 3rd quarter. Marshall Wace LLP now owns 417,789 shares of the medical research company’s stock worth $75,678,000 after buying an additional 355,482 shares during the last quarter. Finally, State Street Corp boosted its stake in IQVIA by 3.8% in the 2nd quarter. State Street Corp now owns 8,622,096 shares of the medical research company’s stock worth $1,870,909,000 after buying an additional 315,751 shares during the last quarter. 86.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Truist Financial began coverage on IQVIA in a report on Friday. They set a “buy” rating and a $265.00 target price on the stock. StockNews.com started coverage on IQVIA in a research report on Thursday. They issued a “hold” rating on the stock. Cowen assumed coverage on IQVIA in a research report on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 target price on the stock. JPMorgan Chase & Co. increased their price target on IQVIA from $257.00 to $263.00 and gave the stock an “overweight” rating in a research note on Monday, February 27th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $265.00 price target on shares of IQVIA in a research note on Monday, February 13th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $256.81.

IQVIA Stock Down 2.8 %

Shares of IQVIA stock traded down $5.54 during trading on Friday, reaching $190.89. The stock had a trading volume of 1,638,466 shares, compared to its average volume of 946,305. The company has a market capitalization of $35.53 billion, a price-to-earnings ratio of 33.43, a P/E/G ratio of 1.97 and a beta of 1.40. The stock has a fifty day moving average price of $218.94 and a two-hundred day moving average price of $208.72. IQVIA Holdings Inc. has a 52 week low of $165.75 and a 52 week high of $254.94. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV – Get Rating) last released its earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.02. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same quarter in the prior year, the company posted $2.42 earnings per share. IQVIA’s revenue was up 2.8% on a year-over-year basis. Sell-side analysts predict that IQVIA Holdings Inc. will post 9.46 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the sale, the insider now owns 1,973 shares in the company, valued at $445,128.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Kevin C. Knightly sold 4,446 shares of the stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the sale, the insider now owns 1,973 shares of the company’s stock, valued at $445,128.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the sale, the insider now directly owns 17,053 shares in the company, valued at approximately $3,922,190. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

IQVIA Profile

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.